Investment Thesis
ResMed demonstrates exceptional fundamental strength with 26.9% net margins, robust 34% operating margins, and impressive free cash flow of $725.6M. The company exhibits financial fortress characteristics with minimal leverage (0.06x debt/equity), strong liquidity (3.06x current ratio), and 55.9x interest coverage, while simultaneously generating high-quality earnings with net income growing 37.2% YoY.
Strengths
- Exceptional profitability with 26.9% net margin and 34% operating margin among highest in medical devices
- Fortress balance sheet: minimal debt at 0.06x D/E ratio, $1.4B cash, and extraordinary 55.9x interest coverage
- Strong cash generation with $725.6M free cash flow and 26.3% FCF margin indicating high-quality earnings
- Operational leverage evident: net income growing 37.2% YoY on 9.8% revenue growth showing cost discipline and efficiency gains
- Excellent liquidity with 3.06x current ratio and 2.32x quick ratio providing significant financial flexibility
Risks
- Net income acceleration (37.2%) significantly outpacing revenue growth (9.8%) requires verification of sustainability and potential one-time items
- Moderate ROE of 11.7% despite exceptional profitability suggests capital efficiency concerns or asset-heavy business model
- Medical device sector exposure to regulatory changes, reimbursement pressures, and competitive innovation threats
- Elevated insider trading activity (10 Form 4 filings in 90 days) warrants monitoring for directional signals
- Low capital expenditure ($71.5M on $2.8B revenue) may indicate underinvestment in future growth initiatives
Key Metrics to Watch
- Gross margin sustainability and trend to verify profitability is not artificially elevated
- Drivers behind net income outperformance vs revenue growth to assess one-time vs recurring benefits
- Operating expense ratios and headcount trends to validate operational leverage claim
- Free cash flow conversion and capital allocation priorities given strong cash generation
- Revenue growth trajectory and segment performance to confirm 9.8% growth is sustainable
Financial Metrics
Revenue
2.8B
Net Income
741.1M
EPS (Diluted)
$5.05
Free Cash Flow
725.6M
Total Assets
8.5B
Cash
1.4B
Profitability Ratios
Gross Margin
61.6%
Operating Margin
34.0%
Net Margin
26.9%
ROE
11.7%
ROA
8.7%
FCF Margin
26.3%
Balance Sheet & Liquidity
Current Ratio
3.06x
Quick Ratio
2.32x
Debt/Equity
0.06x
Debt/Assets
25.7%
Interest Coverage
55.94x
Long-term Debt
403.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T03:27:22.649580 |
Data as of: 2025-12-31 |
Powered by Claude AI